2021.02.05 Proposed Registered Secondary Public Offering of American Depositary Shares by Certain Selling Shareholders of I-Mab
2021.02.05 I-Mab Announces Multiple Clinical Advancements of its Differentiated CD73 Antibody Uliledlimab in China and the U.S.
2021.02.04 I-Mab Announces First Patient Dosed in Phase 2 Clinical Trial of TJ107 in Glioblastoma Multiforme in China
2021.01.25 I-Mab and MorphoSys Announce First Patient Dosed in U.S. Phase 1 Study of TJ210/MOR210 in Patients with Advanced Cancer
2020.12.04 I-Mab Accelerates Clinical Development of Anti-CD47 Monoclonal Antibody Lemzoparlimab in the US and China